Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. Pulmonary surfactant impacts in vitro activity of selected antifungal drugs against Candida krusei and Candida albicans.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
   Article
2. Pharmacodynamic and immunological interactions of amphotericin B formulations and voriconazole with human neutrophils against mature Scedosporium apiospermum and Fusarium spp. biofilms.The Journal of antimicrobial chemotherapy · 2023
   Article
3. Liposomal amphotericin B-the future.The Journal of antimicrobial chemotherapy · 2022
   Article
4. Frontiers in microbiology · 2020
   Article
5. Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
   Review
6. Understanding Pathogenesis and Care Challenges of Immune Reconstitution Inflammatory Syndrome in Fungal Infections.Journal of fungi (Basel, Switzerland) · 2018
   Review
7. Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis.The Journal of infectious diseases · 2013
   Article
8. It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug.Frontiers in microbiology · 2012
   Article
9. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.Antimicrobial agents and chemotherapy · 2010
   Article
10. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study.Haematologica · 2010
    Article
11. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.Drugs · 2009
    Review
12. In vitro determination of phagocytosis and intracellular killing of Aspergillus species by mononuclear phagocytes.Mycopathologia · 2007
    Article
13. Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus.Antimicrobial agents and chemotherapy · 2006
    Article
14. Combination treatment of invasive fungal infections.Clinical microbiology reviews · 2005
    Review
15. Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals.Antimicrobial agents and chemotherapy · 2004
    Article
16. Heat-treated Fungizone retains amphotericin B antifungal activity without renal toxicity in rats infected with Aspergillus fumigatus.Pharmaceutical research · 2004
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as